https://www.selleckchem.com/products/azd0095.html
To analyze if exposure to sunitinib in the SURTIME trial which investigated opposite sequences of cytoreductive nephrectomy (CN) and systemic therapy is associated with the overall survival (OS) benefit observed in the deferred CN arm. A post-hoc analysis of SURTIME trial data. Variables analysed included number of patients receiving sunitinib, time from randomisation to start sunitinib, overall response rate (ORR) by RECIST 1.1, and duration of drug exposure and dose in the intention-to-treat population of the immediate and deferred ar
Curtir
Comentario
Compartilhar
